-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Hengrui Medicine Carrelizumab was approved as the first-line treatment for nasopharyngeal carcinoma, which is its sixth indication |
On June 10, Hengrui Medicine (600276.
SH) announced that its self-developed PD-1 inhibitor carrelizumab (trade name: Erica) was officially approved and issued by the National Medical Products Administration.
The "Drug Registration Certificate" approves carrelizumab combined with cisplatin and gemcitabine for the first-line treatment of patients with locally recurring or metastatic nasopharyngeal carcinoma
.
This indication is the first approved first-line nasopharyngeal carcinoma indication in the world, and it is also approved after Hodgkin’s lymphoma, liver cancer, lung cancer, esophageal squamous cell carcinoma, second-line nasopharyngeal carcinoma and above.
The sixth indication
.
Up to now, carrelizumab is still the domestic PD-1 inhibitor with the most approved indications
According to Hengrui Medicine, the approval of the new indication of Carrelizumab is based on the CAPTAIN-1ST study
.
CAPTAIN-1 study
Hengrui Medicine stated that the above research results have been presented orally at the 2021 American Society of Clinical Oncology (ASCO) annual meeting, and the full text has also been accepted by The Lancet Oncology and will be released in the near future.
.
Four domestic PD-1s have been approved, and the continuous expansion of their indications has become the focus of competition among companies
.
In terms of nasopharyngeal cancer, in addition to Hengrui Medicine’s carrelizumab, Junshi Bio (688180.
During the annual meeting of the American Society of Clinical Oncology (ASCO), a global multicenter, randomized, double-blind, placebo-controlled phase III clinical study of teriprizumab combined with chemotherapy in the first-line treatment of recurrent/metastatic nasopharyngeal carcinoma (JUPITER-02) The latest results are also announced, showing that compared with chemotherapy alone, terreplimumab combined with gemcitabine chemotherapy can achieve better progression-free survival (PFS) and higher objective remission in the first-line treatment of recurrent/metastatic nasopharyngeal carcinoma Rate (ORR) and longer duration of remission (DOR), and has good safety and tolerability
.
At the just-concluded 2021ASCO annual meeting, Hengrui Medicine and Junshi Bio-PD-1 inhibitors both announced numerous research progress
.
According to Hengrui Medicine, Carrelizumab has been selected in 38 studies, covering 11 cancer types including breast cancer, gastrointestinal tumors, lung cancer, and pancreatic cancer; Junshi Biology official website shows that during the ASCO annual meeting, there are Ten phase II studies in the adjuvant/neo-adjuvant/perioperative treatment of non-small cell lung cancer, esophageal cancer, gastric cancer, mucosal melanoma and other fields with teriprizumab have been unveiled
It is foreseeable that in the future, domestic PD-1 inhibitors will have more intense competition in indications
Admiral